A polypeptide and its application in promoting cell proliferation

By activating the LRP5 receptor with the synthesized peptide LR10-9A, the problem of weak keratinocyte proliferation ability was solved, achieving the effects of skin barrier repair and wound healing, and can be applied in cosmetics and pharmaceuticals.

CN123106835APending Publication Date: 2026-11-17GUANGZHOU JINARISHENG BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611500548.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively promote the proliferation of keratinocytes, leading to a decline in skin barrier function and triggering a series of skin problems, such as dry skin, sensitivity, slow wound healing, and microbial imbalance.

Method used

A polypeptide with the amino acid sequence GFFKRVLISCLQA (LR10) was designed and synthesized. It activates the Wnt signaling pathway by activating the target protein LRP5, thereby promoting the proliferation of keratinocytes and skin fibroblasts. Specifically, the polypeptide LR10-9A, as shown in SEQ ID No:2 or SEQ ID No:9, significantly enhances the proliferative capacity through amino acid sequence optimization.

Benefits of technology

The peptide LR10-9A significantly promotes the activity of HaCaT cells and HFF-1 cells in a concentration gradient-dependent manner, and has the potential to strongly promote skin barrier repair and wound healing, making it suitable for use in cosmetics and pharmaceuticals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106835A_ABST
    Figure CN123106835A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedicine, and specifically relates to a polypeptide and its application in promoting cell proliferation. The polypeptide provided by this invention is a small molecule polypeptide with the amino acid sequence SEQ ID No:2 or SEQ ID No:9. This small molecule polypeptide can promote the proliferation of skin keratinocytes and skin fibroblasts. This peptide has a small molecular weight, can be chemically synthesized, has high purity, higher biosafety, and broader application prospects, with the potential to be used in the preparation of cosmetics or drugs for skin repair and wound healing.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedicine, and in particular relates to a polypeptide and its application in promoting cell proliferation. Background Technology

[0002] The skin is the largest human organ, covering the body surface and directly exposed to the external environment, playing a vital protective barrier role. Structurally, the skin consists of the epidermis, dermis, subcutaneous tissue, and various skin appendages. The epidermis, located as the outermost layer of the skin, has an important skin barrier function. It is mainly composed of keratinocytes and is divided into the basal layer, spinous layer, granular layer, and stratum corneum.

[0003] Keratinocytes play multiple key roles in skin repair. They are the executors of the re-epithelialization process, repairing the epidermal barrier through migration, proliferation, and differentiation. Keratinocytes are not only structural units but also play a crucial role in maintaining overall skin homeostasis, ultimately giving the skin a soft and warm feel—qualities essential for skin health. Keratinocytes divide in the basal and spinous layers, but their proliferative capacity diminishes in aging skin.

[0004] Under normal circumstances, the proliferation, migration, and differentiation of keratinocytes are highly regulated, enabling the epidermis to develop into a complete stratum corneum. The stratum corneum plays a crucial role in the skin barrier. A normal and intact stratum corneum can effectively resist damage from the external environment and the loss of body moisture. On the other hand, the stratum corneum can sense changes in external conditions and, after skin damage, can transmit signals to the deeper layers of the skin to mobilize the body's repair function of the skin barrier.

[0005] Once the skin barrier is damaged, the skin's defense function declines significantly, leading to a series of problems such as increased transepidermal water loss, dry and sensitive skin, slow wound healing, microbial imbalance, decreased immune function, and accelerated aging. Abnormalities in the structure and function of the skin barrier are not only typical manifestations of many skin diseases but also important causes, such as atopic dermatitis, eczema, psoriasis, and ichthyosis. More seriously, these skin diseases themselves are accompanied by skin barrier damage; if the barrier function is not repaired in time, the body will be in a state of chronic inflammation, which will further aggravate the original disease and even induce other diseases.

[0006] Therefore, maintaining and repairing the skin barrier function not only helps improve skin condition but also helps prevent and treat skin diseases. Researching and developing a new skin barrier repair product has broad clinical application prospects and market value. Summary of the Invention

[0007] Based on this, the purpose of the present invention is to overcome the defects or deficiencies of the prior art and provide a polypeptide, the amino acid sequence of which is shown in SEQ ID No:2 or SEQ ID No:9.

[0008] Compared to existing technologies, the polypeptide described in this invention has a small molecular weight, can be chemically synthesized, has high purity, higher biosafety, and broader application prospects. It possesses potent proliferative capacity and has the potential to be used in the preparation of cosmetics, skin repair drugs, and wound healing agents. Furthermore, this polypeptide can activate the Wnt signaling pathway by activating the target protein LRP5, and has the potential to be used to prepare Wnt signaling pathway agonists.

[0009] The present invention also provides the use of the described polypeptide in the preparation of drugs that promote cell proliferation.

[0010] In one embodiment, the promotion of cell proliferation is the promotion of skin keratinocyte proliferation and / or the promotion of skin fibroblast proliferation.

[0011] In one embodiment, the skin keratinocytes are HaCaT cells, and the skin fibroblasts are HFF-1 cells.

[0012] In one embodiment, the active ingredient of the drug includes at least a polypeptide with an amino acid sequence as shown in SEQ ID No:2.

[0013] The present invention also provides the use of the described polypeptide in the preparation of medicaments that promote skin repair and / or wound healing.

[0014] The present invention also provides a composition, wherein the composition is a pharmaceutical composition or a cosmetic composition; the active ingredient of the composition includes at least one polypeptide with an amino acid sequence such as SEQ ID No:2 or SEQ ID No:9.

[0015] In one embodiment, the active ingredient of the pharmaceutical composition includes at least a polypeptide with an amino acid sequence as shown in SEQ ID No:2.

[0016] In one embodiment, the concentration of the polypeptide in the composition is 12.5~1000 μM.

[0017] In one embodiment, the pharmaceutical composition has the effect of promoting skin barrier repair or promoting skin cell proliferation.

[0018] The present invention also provides the use of the described polypeptide or the pharmaceutical composition in the preparation of cell culture medium additives that promote cell proliferation.

[0019] To better understand and implement this invention, the following detailed description is provided in conjunction with the accompanying drawings. Attached Figure Description

[0020] Figure 1 The effect of peptide LR10 on HaCat cell viability under different treatment concentrations and times.

[0021] Figure 2 The effect of peptide LR10 on HaCat cell morphology.

[0022] Figure 3 The results show the performance comparison between LR10 and LR10-9A.

[0023] Figure 4 The effect of different treatment concentrations and times on the viability of HaCat cells.

[0024] Figure 5 The effect of different treatment concentrations and times on the viability of HFF-1 cells.

[0025] Figure 6 Effects of a shortened peptide variant of LR10-9A on HaCat cell morphology.

[0026] Figure 7 Effects of allosteric peptide variants of LR10-9A on HaCat cell viability. Detailed Implementation

[0027] In previous studies, this invention screened potential candidate proteins from *Planaria guangiana* that could interact with the LRP5 receptor, and investigated the binding sites of the screened candidate proteins to the LRP5 receptor. Then, candidate peptides with sequences of 10-13 amino acids were designed based on the amino acid residues at the binding sites. By comparing the effects of the candidate peptides on the proliferation of skin keratinocytes, the candidate peptide LR10 was selected, with the amino acid sequence GFFKRVLISCLQA (SEQ ID No: 1).

[0028] The theoretical isoelectric point of LR10 is 9.51, its molecular weight is 1481.82, and its molecular formula is C10. 69 H 112 N 18 O 16 S1, with an aliphatic index of 120.00 and a GRAVY index of 1.008, exhibits good thermal stability and excellent hydrophobicity. To confirm the basic activity of LR10, previous studies examined its proliferative effect on HaCaT human skin keratinocytes. Results showed that the peptide LR10 promoted increased HaCaT cell viability in a concentration-gradient manner, with well-defined cell morphology and a significant increase in cell number (e.g., ...). Figure 1 and Figure 2 As shown in the figure, LR10 has a clear keratinocyte proliferation-promoting activity.

[0029] Building upon this foundation, previous research further elucidated the active backbone of LR10 through systematic truncation and alanine scanning, identifying arginine at position 5, isoleucine at position 8, and cysteine ​​at position 10 as its core functional sites. During this process, the previous research unexpectedly discovered that the polypeptide variant LR10-9A (SEQ ID No:2), obtained by mutating serine at position 9 to alanine, exhibited significantly superior proliferative activity compared to the parent LR10 under the same experimental conditions (e.g., ...). Figure 3 (As shown).

[0030] Further analysis revealed the structural basis for this mutation's enhanced activity: the 9th position was mutated from a serine (containing a hydroxyl group, hydrophilic) to an alanine (methyl group, hydrophobic), reducing the local hydrophilicity at that site. Considering that LR10 already has a GRAVY index of 1.008 (strong hydrophobicity), this mutation further enhances the peptide's hydrophobic properties, potentially promoting its matching with the hydrophobic microenvironment of the LRP5 receptor, thereby improving binding stability and activation efficiency without disrupting the core binding mode.

[0031] However, while previous studies have preliminarily elucidated the active skeleton of LR10 and discovered the potential for optimization at position 9, the following key questions remain: First, can the variant LR10-9A obtained after optimization at position 9 be further truncated to shorten the sequence and reduce synthesis costs? Second, is alanine the optimal amino acid type for position 9, or are there other hydrophobic residues that could produce better results? Therefore, based on previous structure-activity relationship studies, this invention uses LR10-9A as a new lead compound to further conduct truncation screening and saturation mutagenesis at position 9, aiming to elucidate its fine structure-activity relationship and confirm the optimal sequence.

[0032] Before conducting structural optimization, this invention first performed a systematic dose- and time-dependent evaluation of LR10-9A to confirm its activity characteristics and establish an activity benchmark for subsequent optimization. In the optimization study, this invention used the immortalized human keratinocyte cell line HaCaT for cell experiments; HaCaT cells are one of the main cell models for cosmetic development.

[0033] The method for determining the proliferative activity of the peptide variant LR10-9A on HaCaT cells specifically includes the following steps: (1) Cell Culture and Plating: HaCat cells were routinely cultured in DMEM high-glucose medium containing 10% fetal bovine serum and 1% penicillin-streptomycin in a constant temperature incubator at 37°C and 5% CO2. Cells in the logarithmic growth phase were digested with trypsin, counted, and then plated at 5 × 10⁶ cells per well. 3Cells were evenly seeded at a density of 100 μL in each well of a 96-well plate. The plates were then pre-cultured in an incubator for 12–24 h to allow the cells to adhere fully.

[0034] (2) The 100 μmM LR10-9A peptide solution was serially diluted to 100 μM, 50 μM, 25 μM and 12.5 μM in complete medium containing 1% DMSO. After discarding the original medium, the LR10-9A peptide solutions of different concentrations were added to the corresponding wells. At the same time, a cell control group containing only 1% DMSO and a blank group without cells were set up. CCK8 assay was performed at three time points: 24 h, 48 h and 72 h after peptide treatment. Before assay, the CCK8 working solution was prepared according to the kit instructions. After discarding the original solution in each well, 100 μL of the working solution was added. After adding the CCK8 working solution, the culture plate was placed back in the incubator and incubated in the dark for 1-2 h.

[0035] (3) Absorbance measurement and data processing: After incubation, the absorbance (OD value) of each well was measured at a wavelength of 450 nm using a multi-functional microplate reader. After zeroing with blank wells, cell viability was expressed as a percentage relative to the control group. The calculation formula was: Cell viability (%) = [(OD peptide treatment group - OD blank group) / (OD control group - OD blank group)] × 100%.

[0036] Please see Figure 4 LR10-9A promoted the increase of HaCaT cell viability in a concentration gradient range of 12.5–100 μM, and showed a stable time-effect relationship at 24 h, 48 h, and 72 h. These results systematically confirmed the proliferative activity of LR10-9A, providing a reliable activity benchmark for its use as a lead compound in subsequent truncation and saturation mutagenesis studies.

[0037] After confirming that LR10-9A has significant pro-proliferative activity against HaCaT cells, this invention further evaluates its broad-spectrum effects on skin repair-related cells. Skin repair not only depends on the proliferation of keratinocytes but also requires the secretion of extracellular matrix such as collagen by dermal fibroblasts. Therefore, this invention examines the effect of LR10-9A on the viability of HFF-1 human skin fibroblasts.

[0038] Please see Figure 5The peptide LR10-9A enhanced HFF-1 cell viability in a concentration gradient-dependent manner. These results suggest that LR10-9A may also have a positive effect on dermal cells while promoting epidermal cell proliferation. Given that keratinocytes are responsible for re-epithelialization and fibroblasts are responsible for collagen secretion and extracellular matrix reconstruction, the dual promoting effect of LR10-9A on both cell types indicates its potential for full-thickness skin repair, rather than being limited to a single epidermal effect.

[0039] Based on the above confirmation of the activity characteristics and broad-spectrum activity of LR10-9A, this invention further optimizes the structure of LR10-9A. First, truncation screening is performed, and the amino acid sequences of the peptide variants are shown in SEQ ID Nos. 3-8. Then, the activities of different peptide variants are compared using the CCK8 assay. Please refer to [link to relevant documentation]. Figure 6 The shortened peptide variant of LR10-9A exhibited weaker proliferative activity in HaCaT cells. This result indicates that LR10-9A requires a certain amino acid sequence length to ensure adequate binding to the receptor. Although previous studies have identified the core active backbone FKRVLISC, the N-terminal and C-terminal helper sequences remain essential for maintaining high activity. Excessively short sequences may lead to conformational instability or insufficient interfacial contact area, thereby weakening receptor activation efficiency.

[0040] Truncating experiments showed that the complete sequence of LR10-9A is essential for maintaining high activity. Therefore, this invention further focuses on the 9th amino acid itself, mutating it into different hydrophobic residues while maintaining the full-length sequence, to verify whether alanine is the optimal choice for this position. The amino acid sequences of the peptide variants are shown in SEQ ID No:9 and SEQ ID No:10.

[0041] Please see Figure 7 When the 9th position is mutated to threonine (LR10-9T, its amino acid sequence is shown in SEQ ID No:9) or valine (LR10-9V, its amino acid sequence is shown in SEQ ID No:10), the polypeptide variant still exhibits cell proliferation-promoting activity, but the activity is weaker than that of LR10-9A. This result further confirms that the optimal choice for the 9th position is a small, non-β-branched hydrophobic residue. Threonine is highly hydrophilic due to the retention of its hydroxyl group, while valine, although hydrophobic, suffers from increased steric hindrance due to β-branching, both of which are unfavorable for receptor binding; while alanine has the smallest methyl side chain and is unbranched, achieving the best balance between hydrophobic complementarity and steric adaptation.

[0042] In summary, LR10-9A, with an amino acid sequence as shown in SEQ ID No:2, exhibits the strongest cell proliferation-promoting activity, superior to the parent LR10, and has the potential to be used in the preparation of drugs or cosmetics for repairing the skin barrier and promoting wound healing.

[0043] Based on the above research results, the present invention provides a polypeptide whose amino acid sequence is SEQ ID No:2 or SEQ ID No:9.

[0044] Furthermore, the present invention also provides the use of the polypeptide in the preparation of skin repair drugs or wound healing promotion drugs.

[0045] The present invention also provides the application of the polypeptide in the preparation of cosmetics, wherein the cosmetics can promote the proliferation of skin keratinocytes, wherein the skin keratinocytes are HaCaT cells.

[0046] The cosmetic product can also promote the proliferation of skin fibroblasts, which are HFF-1 cells.

[0047] The drug comprises the polypeptides of the present invention and medically acceptable excipients, including fillers, binders, lubricants, disintegrants, or stabilizers.

[0048] The drug is a topical dosage form formed by combining the polypeptide with a water-soluble matrix or a lipid-soluble matrix.

[0049] The external dosage form is an ointment, paste, powder, or gel.

[0050] The present invention also provides a method for synthesizing the polypeptide, comprising solid-phase synthesis in sequence of amino acids from the C-terminus to the N-terminus of the polypeptide.

[0051] Specifically, the protective amino acid raw material and the resin are coupled one by one according to the C-terminus to N-terminus amino acid sequence of any one of the amino acid sequences in SEQ ID No:1~10. Then, the resin and the protecting groups of the side chains of the protective amino acids are removed by the lysis buffer to obtain the crude product. After purification of the crude product, the synthetic polypeptide is obtained.

[0052] The N-terminus of the protected amino acid is protected with Fmoc.

[0053] The resin may be 2-chlorotriphenylchloro resin or others.

[0054] Specifically, the synthesis method includes the following steps: S1. The amino acids are sequentially coupled to the resin to form a peptide chain. After the sequence synthesis is completed, the N-terminal Fmoc protecting group is deprotected or the N-terminus is modified before the side chain protecting groups are deprotected, and the peptide is cleaved from the resin.

[0055] Step S1 includes the following steps: S11. Coupling the first amino acid: Take an appropriate amount of modified resin, add the prepared amino acid solution and coupling reagent to the resin, and react for a period of time. The resin used may include Cl-Resin, Rink Amide Resin, etc. In this embodiment, if the C-terminus of the sequence is COOH, then Cl-Resin is used; if the C-terminus is CONH2, then Rink Amide Resin is used.

[0056] S12. Removal of Fmoc: After adding piperidine solution (20% Pip + DMF) for a period of time, remove the solvent by vacuum filtration.

[0057] S13. Washing: Add DMF to the resin and wash, then remove the solvent by vacuum filtration.

[0058] S14. Resin Test: Place test reagents A and B and a small amount of resin into a test tube. Then place the test tube in a metal bath for a few seconds and check if the resin color changes. If the resin color changes, the Fmoc group has been successfully removed.

[0059] S15. Amino Acid Condensation: Add the prepared amino acid solution to the resin. Then add the coupling reagent, shake well for a period of time, and remove the solvent by vacuum filtration. The condensation reagent is DIC (N,N-diisopropylcarbodiimide) + HOBT (1-hydroxybenzotriazole); HATU / HBTU / HCTU + DIEA, where HATU is O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate, HBTU is O-(benzotriazole-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate, HCTU is O-(6-chlorobenzotriazole-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate, and DIFA is N,N-diisopropylethylamine.

[0060] S16. Repeat steps S12-S15 until the synthesis of the last amino acid is completed, and obtain the crude peptide sample.

[0061] S2. Purification, which includes the following steps: S21. Dissolving the crude peptide sample: Based on the properties of the sequence, select an appropriate reagent to completely dissolve the crude peptide sample. Acetonitrile and deionized water were used in practice, with TFA (0.01% TFA) as the buffer.

[0062] S22. Set the purification gradient: Design the purification gradient based on the sequence properties.

[0063] S23. The crude peptide sample was filtered through a 0.45-micron filter membrane and then injected into a high-performance liquid chromatograph (HPLC). The absorption peaks in the chromatogram were collected individually. This embodiment uses reversed-phase HPLC.

[0064] S24. Test the molecular weight and purity of the fraction to determine the target fraction.

[0065] Compared with the prior art, the polypeptide LR10-9A provided by the present invention has a strong ability to promote the proliferation of keratinocytes and has the potential to be used in the preparation of cosmetics, cell culture medium additives that promote cell proliferation, skin repair drugs, or wound healing drugs.

[0066] The embodiments described above are merely examples of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention.

Claims

1. A polypeptide, characterized in that, The amino acid sequence of the polypeptide is SEQ ID No:2 or SEQ ID No:

9.

2. The use of the polypeptide of claim 1 in the preparation of a drug that promotes cell proliferation.

3. The application according to claim 2, characterized in that, The promotion of cell proliferation refers to the promotion of skin keratinocyte proliferation and / or the promotion of skin fibroblast proliferation.

4. The application according to claim 3, characterized in that, The skin keratinocytes are HaCaT cells, and the skin fibroblasts are HFF-1 cells.

5. The application according to claim 2, characterized in that, The active ingredient of the drug includes at least a polypeptide with an amino acid sequence as shown in SEQ ID No:

2.

6. The use of the polypeptide of claim 1 in the preparation of a medicament for promoting skin repair and / or wound healing.

7. A pharmaceutical composition, characterized in that, The active ingredient of the pharmaceutical composition includes at least one polypeptide with an amino acid sequence such as SEQ ID No:2 or SEQ ID No:

9.

8. The pharmaceutical composition according to claim 7, characterized in that, The active ingredient of the pharmaceutical composition includes at least a polypeptide with an amino acid sequence as shown in SEQ ID No:

2.

9. The pharmaceutical composition according to claim 7, characterized in that, The concentration of the polypeptide in the composition is 12.5~1000 μM.

10. The pharmaceutical composition according to claim 7, characterized in that, The pharmaceutical composition has the effect of promoting skin barrier repair or promoting skin cell proliferation.

11. The use of the polypeptide of claim 1 or the pharmaceutical composition of any one of claims 7 to 10 in the preparation of a cell culture medium additive that promotes cell proliferation.